PharmaCyte stockholders authorize share issuance and approve 2.25M share increase to equity plan

PharmaCyte Biotech, Inc.

Stockholders authorized issuance of shares underlying convertible preferred stock and warrants per August 2025 SPA (1,649,395 for, 249,100 against).
Amendment to 2022 Equity Incentive Plan approved, increasing share reserve by 2,250,000 shares (2,348,827 for, 399,696 against).
All three proposals passed at special meeting on Oct 30, 2025, with ~37.1% quorum (2,866,944 shares voted).
Proposal 3 (adjournment) also passed: 2,496,898 for, 311,836 against, 58,210 abstentions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.